Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CELESTICA INCCLS · Entity 3096 | Director | September 30, 2026 | October 02, 2026 |
| KORU Medical Systems, Inc.KRMD · Entity 6517 | Director | October 01, 2026 | October 01, 2026 |
| Mirion Technologies, Inc.MIR · Entity 394 | Director | May 13, 2026 | May 14, 2026 |
| Neuronetics, Inc.STIM · Entity 6248 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CELESTICA INC
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 272 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 52 · Balance 278 Row 2 · 2026-09-30 · Tax withholding · Disposed 6 · Balance 272 F1: Shares withheld to satisfy tax withholding obligations arising out of the vesting of restricted share units ("RSUs"). |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 105 |
Reported balance
After 2026-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-30 · Exercise / conversion · Disposed 52 · Balance 105 F2: Each RSU represents a contingent right to receive one common share or an equivalent value in cash at the holder's election. F3: On September 30, 2025, the reporting person was granted 157 RSUs, 1/3 of which vest annually over 3 years on the anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax withholding obligations arising out of the vesting of restricted share units ("RSUs").
F2: Each RSU represents a contingent right to receive one common share or an equivalent value in cash at the holder's election.
F3: On September 30, 2025, the reporting person was granted 157 RSUs, 1/3 of which vest annually over 3 years on the anniversary of the grant date.
KORU Medical Systems, Inc.
Report date October 01, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 103,274 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 5,119 · Balance 103,274 |
Mirion Technologies, Inc.
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 60,801 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 7,383 · Balance 60,801 F1: Represents restricted stock units that will vest on the earlier to occur of (i) first anniversary of the grant date or (ii) date of the annual stockholder meeting following the grant date, subject to the non-employee director's continued service on the Board through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that will vest on the earlier to occur of (i) first anniversary of the grant date or (ii) date of the annual stockholder meeting following the grant date, subject to the non-employee director's continued service on the Board through such vesting date.
Neuronetics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 625,017 |
Reported balance
After 2026-05-28 transaction · row 1
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 36,250 · Balance 625,017 F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027 or (b) the Reporting Person's Board-approved separation of service from the Issuer or change in control of the Issuer, in each case subject to continuous service of the Reporting Person through such date. F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027 or (b) the Reporting Person's Board-approved separation of service from the Issuer or change in control of the Issuer, in each case subject to continuous service of the Reporting Person through such date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jul 5, 2023 20:11 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 4,310 | $3.48 | $14,998.80 |
DisclosureSEC source: 0001161697-23-000388 · form_4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,478 Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 21:11 UTC | Mirion Technologies, Inc. MIR · Entity 394 | GrantClass A Common Stock | 11,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-021322 · wk-form4_1686172273.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,941 F1 · shares: Represents restricted stock units that will vest in four equal quarterly installments on September 15, 2023, December 15, 2023, March 15, 2024, and June 15, 2024, subject to the non-employee director's continued service on the Board through each such vesting date. Read SEC document |
| May 25, 2023 Filed May 30, 2023 21:58 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 45,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-012469 · form4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,348 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 23, 2024, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 20:03 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,521 | $4.26 | $14,999.46 |
DisclosureSEC source: 0001161697-23-000211 · form_4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,971 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 20:04 UTC Amendment | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,521 | $4.26 | $14,999.46 |
DisclosureSEC source: 0001161697-23-000231 · form_4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,168 Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:45 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 4,273 | $3.51 | $14,998.23 |
DisclosureSEC source: 0001161697-23-000021 · form_4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,647 Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:49 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 6,681 | $2.25 | $15,032.25 |
DisclosureSEC source: 0001161697-22-000491 · form_4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,693 Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 22:15 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,693 | $2.50 | $9,232.50 |
DisclosureSEC source: 0001161697-22-000340 · form_4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,693 Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 19:26 UTC | Mirion Technologies, Inc. MIR · Entity 394 | GrantCommon Stock | 14,274 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-017418 · wf-form4_165549399757002.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,091 F1 · shares: Represents restricted stock units that will vest in four equal quarterly installments on September 15, 2022, December 15, 2022, March 15, 2023, and June 15, 2023, subject to the non-employee director's continued service on the Board through each such vesting date. Read SEC document |
| May 26, 2022 Filed May 31, 2022 20:29 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 48,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-013872 · form4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,893 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 26, 2023, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 22:15 UTC | Mirion Technologies, Inc. MIR · Entity 394 | GrantCommon Stock | 5,817 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-020496 · dp164366_4-cascella.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,817 F1 · shares: Represents restricted stock units ("RSUs") that will vest in two installments with 3,569 RSUs vesting on March 15, 2022 and 2,248 RSUs vesting on June 15, 2022, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:15 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 15,000 | $4.10 | $61,497.00 |
DisclosureSEC source: 0001062993-21-011594 · form4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,255 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at per share prices ranging from $4.00 to $4.20. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 21:04 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 15,000 | $6.72 | $100,849.50 |
DisclosureSEC source: 0001062993-21-008052 · form4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,255 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at per share prices ranging from $6.65 to $6.80. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 22:29 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 8,922 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-005248 · form4.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,255 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 27, 2022, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:42 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001218713-21-000005 · edgar.xml · nonDerivative · entry 1 CASCELLA ROBERT · CIK 0001218713 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 26, 2021 and (b) the Company's 2021 annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.